AIkido Pharma Sponsors Psychedelic Compound Research To Treat PTSD

AIkido Pharma Inc. is sponsoring psychedelic research at the Mount Sinai Center for Psychedelic Psychotherapy and Trauma Research (Center). The Center examines the therapeutic potential of psychedelic compounds for post-traumatic stress disorder (PTSD) and other trauma-related symptoms.

The Center works to provide novel clinical therapies utilizing methylenedioxymethamphetamine (MDMA), psilocybin, and other psychedelics through U.S. Food and Drug Administration (FDA)-approved research protocols. More specific to Alkido Pharma's support, the Center will be embarking on clinical trials with MDMA and psilocybin. As part of these studies the Center will be collecting blood samples and performing neuroimaging before . . .